Petros Pharmaceuticals Enters General Assignment for Benefit of Creditors — Ceases Operations
PTPI has more than doubled off its 52-week low of $0.002.
Summary
Petros Pharmaceuticals has entered a General Assignment for the Benefit of Creditors, ceasing all operations and assigning assets to a liquidator. The entire board and senior management have departed. This is a liquidation event with no recovery expected for shareholders.
Key Events · Legal and Risk Events · PTPI
-
General Assignment for Benefit of Creditors
On September 30, 2026, Petros Pharmaceuticals entered into a General Assignment for the Benefit of Creditors under California law, assigning all assets to PT Liquidation, LLC as Assignee for the benefit of creditors.
-
Ceased Operations and Going Concern Failure
The company has ceased substantially all business operations and no longer has the ability to continue as a going concern. The Assignee will administer assets to satisfy creditor claims to the extent possible.
-
Acceleration of Obligations and Preferred Stock Redemption
The ABC triggered events of default under contractual obligations and required immediate redemption of all outstanding Series A Convertible Preferred Stock. All outstanding obligations may be immediately due and payable.
-
Full Board and Management Departure
Executive Chairman Joshua N. Silverman, Director Bruce T. Bernstein, and Director Wayne R. Walker resigned. President Fady Boctor was terminated, and Chief Accounting Officer Robert Weinstein resigned, all effective September 30, 2026.
Analysis · PTPI · Life Sciences
Petros Pharmaceuticals has entered a General Assignment for the Benefit of Creditors under California law, assigning all assets to PT Liquidation, LLC. The company has ceased substantially all business operations and no longer has the ability to continue as a going concern. This is a liquidation event, not a reorganization — creditors will receive distributions from the Assignee to the extent possible, and shareholders are likely to receive nothing. The ABC also triggered immediate redemption of all outstanding Series A Convertible Preferred Stock and accelerated all outstanding obligations. The entire board and senior management have resigned or been terminated effective September 30, 2026. This follows the Q2 2026 10-Q filed August 13, 2026, which had already disclosed going concern doubts, material weaknesses, and restated financials. The company's stock trades at $0.0068 per share, and this filing confirms the worst-case outcome for equity holders.
At the time of this filing, PTPI was trading at $0.01 on OTC in the Life Sciences sector, with a market capitalization of approximately $288.1K. The 52-week trading range was $0.00 to $0.03. This filing was assessed with negative market sentiment and an importance score of 10 out of 10.